Project Grant R41AI186746
Award Date
8/1/25
Completion Date
7/31/27
Dollars Obligated
$270K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Colorado, USA
Similar Awards
The federal Project Grant award R01AI189313 for $905,998.00 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research by the Texas Biomedical Research Institute to evaluate the safety, immunogenicity, and efficacy of an attenuated Mycobacterium tuberculosis (MTB) vaccine candidate in the setting of HIV co-infection, using rhesus and cynomolgus macaque models. The goal...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,162,224 to the University of Pittsburgh to optimize an oral BCG (Bacille Calmette-Guérin) vaccine regimen and evaluate its efficacy against tuberculosis (TB) infection. The key objectives are to: 1) Optimize an oral BCG regimen, 2) Compare the efficacy of oral BCG to intravenous and intradermal BCG (current...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $950,092 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Seattle Children's Hospital to develop targeted vaccine candidates against nontuberculous mycobacterial (NTM) infections. The project aims to evaluate the efficacy of two NTM vaccine candidates - an adjuvanted subunit vaccine and a novel replicon RNA-based vaccine - in mouse models. Key research activities include screening...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), will support research to identify and characterize the specific proteins secreted by the ESX5 transport system in Mycobacterium tuberculosis, the causative agent of tuberculosis (TB). The $820,246 award to the Albert Einstein College of Medicine will be used to investigate the roles of these secreted proteins in...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $800,200 to study the mechanisms of interferon-gamma (IFN-γ)-independent T cell and B cell-mediated protection against tuberculosis (TB) in humans. The research aims to elucidate the IFN-γ-independent T cell response and characterize the B cell, antibody, and T follicular helper (Tfh) cell responses in...
This $193,375 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to identify bacterial determinants that may contribute to variable treatment responses for tuberculosis (TB). The project, conducted by researchers at the Harvard T.H. Chan School of Public Health, aims to investigate the effects of clinically prevalent variants in the ESX1 secretion system on TB...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant valued at $718,758 to the Texas Biomedical Research Institute under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant is focused on evaluating the use of IL-21-IgFc fusion protein as a host-directed immunotherapy to improve immune reconstitution and reduce the risk of latent tuberculosis (TB) reactivation in Mycobacterium tuberculosis (MTB) and simian immunodeficiency virus (SIV)...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $2,863,501.00 over a 4-year period starting August 1, 2025 to conduct research on the mechanisms of CD4 T cell help to myeloid cells in tuberculosis (TB). The research aims to define how CD4 T cells, through direct cell-cell contact and indirect pathways, activate myeloid cells to control intracellular Mycobacterium...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $749,414 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Ohio State University for research on the role of macrophage drug efflux pump MDR1 in Mycobacterium tuberculosis (M.TB) pathogenesis. The primary objectives are to: 1) define the role of MDR1 in M.TB survival in macrophages; 2) determine if HSF1 activation or MDR1 inhibition can shorten M.TB sterilization by TB drugs;...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $711,993.00 to Boston Medical Center Corporation to conduct research on the impact of Mycobacterium tuberculosis (MTB) disease on HIV-1 immunity, evolution, and persistence. The research aims to examine how MTB disease affects the development of broadly potent HIV-1 neutralizing antibodies, the emergence of...